Answers are grounded in this paper and cite their sources.
An overview is given of the in vitro test results on MCF-7, a mammary tumour, and WiDr, a colon carcinoma, of several series of organotin compounds synthesized in the Free University of Brussels VUB.Several compounds exhibit a very promising antitumour activity.The solution chemistry of the 2:3 condensation complex of salicylaldoxime with di-n-butyltin oxide is briefly described. Antitumour activity of diorganotin 2,6-pyridinedicarboxylatesWe have been active in the synthesis and characterization of tin-based antitumour compounds for several years and we would like to summarize here the results that have already been patented( 1 ) and that may therefore be disclosed^2).We synthesized and tested in vitro against human tumour cell lines a series of diorganotin 2,6pyridinedicarboxylates, C 5 H 3 N(COO)2SnRR', with different groups R and R' bound to tin.The most active compounds in vitro proved to be the din-butyl ones: they are characterized by inhibition doses ID 50 of 60 and 106 ng/mL, respectively, against two human cancer cell lines, MCF-7, a mammary tumour, and WiDr, a colon carninoma( 2 ).For cisplatin, the ID 50 values obtained for the same tumour cell lines are 850 and 624 ng/mL, respectively. Antitumour activity of diorganotin dicarboxylatesWe also prepared diorganotin derivatives of substituted salicylic acids^2).Here, two types of compounds can be synthesized depending from the molar ratio carboxylic acid: diorganotin oxide used to prepare them.When a 2:1 molar ratio is used, the expected diorganotin dicarboxylate is formed.The structure of diethyltin bis(2-methylthio-3-pyridinecarboxylate)( 3 ) is given as illustration:
No takes yet. Share an insight, caveat, or question.
Marcel Gielen (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: